Story
In July 2023, Migrasome Therapeutics (Beijing) Co., Ltd. completed an Angel+ equity financing round of more than RMB 100 million. The round was led by the Zhongguancun Collaborative Innovation Fund, with participation from multiple institutions.
The proceeds will support the company’s drug-delivery platform and therapeutic programs based on original migrasome biology, while also strengthening its R&D, production and quality-control capabilities.
Migrasome Therapeutics was founded in April 2022 in Beijing’s Changping Life Science Park under the leadership of Professor Li Yu of Tsinghua University. Building on Professor Yu’s long-term research in migrasome biology, the company organizes its work around a 3R strategy—Read, Rebuild and Rectify—covering disease analysis, engineered drug delivery, migrasome modulation and diagnostics.
Migrasomes are newly recognized organelles formed during cell migration and involved in intercellular transfer of biological materials and signals. By systematically studying their biology and disease relevance, the company aims to translate an original scientific discovery into validated technologies and products.
The financing will help the company recruit talent, deepen platform development and expand clinical and industry collaboration.